[HTML] Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

[HTML] Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

MJ Armstrong, D Hull, K Guo, D Barton… - Journal of …, 2016 - journal-of-hepatology.eu

Background & Aims Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic
steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2
diabetes, but no prospective experimental data exists in NASH. This study determined the …

For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:

*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.

*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.

*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.

*Peptide Salt: TFA, Desalt, Acetate, HCl.

*Peptide Purity: From crude to ＞99.5%.

*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.

*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.

Quick Links:

Peptide Price
Peptide Modification
Peptide Library
Quote Request
Contact Us

Contact Information:

Eva He
eva@pepmic.com

Pepmic Co., Ltd
www.pepmic.com